These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28141591)

  • 1. Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta.
    Ispiroglu M; Bahcecioglu IH; Demirel U; Yalniz M
    J Infect Dev Ctries; 2017 Jan; 11(1):58-64. PubMed ID: 28141591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients.
    Yilmaz B; Can G; Ucmak F; Arslan AO; Solmaz I; Unlu O; Düzenli S; Korkmaz U; Kurt M; Senates E
    Acta Gastroenterol Belg; 2016; 79(2):206-10. PubMed ID: 27382939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
    Yilmaz E; Baran B; Soyer OM; Onel M; Onel D; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S; Karaca C
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1753-8. PubMed ID: 24582569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.
    Visco-Comandini U; Lapa D; Taibi C; Angeletti C; Capobianchi MR; Garbuglia AR
    Dig Liver Dis; 2014 Apr; 46(4):348-52. PubMed ID: 24387833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
    Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
    J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
    Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
    Nadia K; Hicham E; Reda TM; Nadia T; Elarbi B; Saâd E; Mimoun Z; Saâd M
    Gene; 2015 Aug; 568(1):31-4. PubMed ID: 25958342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
    Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
    Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M
    Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.